Abstract:In Alzheimer's disease (AD) pathophysiology, plaque and tangle accumulation trigger an inflammatory response that mounts positive feed-back loops between inflammation and protein aggregation, aggravating neurite damage and neuronal death. One of the earliest brain regions to undergo neurodegeneration is the locus coeruleus (LC), the predominant site of norepinephrine (NE) production in the central nervous system (CNS). In animal models of AD, dampening the impact of noradrenergic signaling pathways, either through administration of beta blockers or pharmacological ablation of the LC, heightened neuroinflammation through increased levels of pro-inflammatory mediators. Since microglia are the resident immune cells of the CNS, it is reasonable to postulate that they are responsible for translating the loss of NE tone into exacerbated disease pathology. Recent findings from our lab demonstrated that noradrenergic signaling inhibits microglia dynamics via β2 adrenergic receptors (β2ARs), suggesting a potential anti-inflammatory role for microglial β2AR signaling. Thus, we hypothesize that microglial β2 adrenergic signaling is progressively impaired during AD progression, which leads to the chronic immune vigilant state of microglia that worsens disease pathology. First, we characterized changes in microglial β2AR signaling as a function of amyloid pathology. We found that LC neurons and their projections degenerate early and progressively in the 5xFAD mouse model of AD; accompanied by mild decrease in the levels of norepinephrine and its metabolite normetanephrine. Interestingly, while 5xFAD microglia, especially plaque-associated microglia, significant downregulated β2AR gene expression early in amyloid pathology, they did not lose their responsiveness to β2AR stimulation. Most importantly, we demonstrated that specific microglial β2AR deletion worsened disease pathology while chronic β2AR stimulation resulted in attenuation of amyloid pathology and associated neuritic damage, suggesting microglial β2AR might be used as potential therapeutic target to modify AD pathology.

NOGO-A INHIBITS ADHESION AND MIGRATION OF MICROGLIA TO AB IN VITRO

Nogo receptor impairs the clearance of fibril amyloid- by microglia and accelerates Alzheimer's-like disease progression

The Adhesion and Migration of Microglia to Β-Amyloid (aβ) is Decreased with Aging and Inhibited by Nogo/NgR Pathway

The Blockage of the Nogo/NgR Signal Pathway in Microglia Alleviates the Formation of Aβ Plaques and Tau Phosphorylation in APP/PS1 Transgenic Mice

Nogo-66 receptor activation inhibits neurite outgrowth and increases β-amyloid protein secretion of cortical neurons.

Function of Nogo‐A/Nogo‐A Receptor in Alzheimer's Disease

Nogo‐66 Inhibits Adhesion and Migration of Microglia Via GTPase Rho Pathway in Vitro

Interaction Between Amyloid Precursor Protein and Nogo Receptors Regulates Amyloid Deposition

Increased expression of the Nogo receptor in the hippocampus and its relation to the neuropathology in Alzheimer's disease

Nogo‐66 promotes β‐amyloid protein secretion via NgR/ROCK‐dependent BACE1 activation

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

The Difference in Gliosis Induced by Β-Amyloid and Tau Treatments in Astrocyte Cultures Derived from Senescence Accelerated and Normal Mouse Strains

Expression of NgR1-Antagonizing Proteins Decreases with Aging and Cognitive Decline in Rat Hippocampus

The Nogo/Nogo Receptor (ngr) Signal is Involved in Neuroinflammation Through the Regulation of Microglial Inflammatory Activation.

Noradrenergic signaling controls Alzheimer's disease pathology via activation of microglial β2 adrenergic receptors

Ginkgolide B inhibits NLRP3 inflammasome activation and promotes microglial M2 polarization in A<sub>1-42</sub>-induced microglia cells

Nogo-A Drives Alzheimer's Disease Progression by Inducing Tauopathy Vulnerability.

Downregulation of miR-181c-5p in Alzheimer's disease weakens the response of microglia to Aβ phagocytosis

Expressions of Nogo A and its receptor in the cerebrums of patients with Alzheimer disease

Involvement of RhoA/ROCK Signaling in Aβ-Induced Chemotaxis, Cytotoxicity and Inflammatory Response of Microglial BV2 Cells

Microglial cell dysregulation in brain aging and neurodegeneration